NASH Biomarkers – Presentations

Friday 5 May 2017 - Day 1

  Session 1: Priorities in Biomarker Development for NASH
Chairs: Veronica Miller & Arun Sanyal

Tetri, Brent 2017 120

A pathologist, a radiologist and a hepatologist walked into a bar
Brent Tetri, MD
Saint Louis University Health Sciences Center, St. Louis, MO, USA



Innovation in histological assessment of NASH
Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France


  Session 2: Pathways to Biomarker Qualification and Acceptance
Chair: Chris Leptak & Veronica Miller

Stein, Peter 120

View from the Top - Potential impact of 21st Century Cures Act?
Peter Stein, MD
FDA Center for Drug Evaluation and Research, Silver Spring, MD 

>Presentation (not available)


EU Perspective
Elmer Schabel, MD
European Medicines Agency, London, UK & BfArM, Bonn, Germany



Collaboration in action: BEST
Chris Leptak, MD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD



Collaboration in action: FNIH
Roberto Calle, MD, FACE, FACP
Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA



Collaboration in action: IMI
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom


  Session 3: Circulating biomarkers
 Chairs: Sudha Shankar & Brent Tetri

Puri, Puneet (from web) 120x160

Lipidomics and Proteomics
Puneet Puri, MD
Virginia Commonwealth University, Richmond, VA, USA

>Presentation (not available)


Role of Genetic assessments
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom



Francque, Sven 2017 120

Circulating nucleic acids and combination panels
Sven Francque MD, PhD
Antwerp University Hospital, Antwerp, Belgium


  Session 4: Imaging Biomarkers
  Chairs: Quentin Anstee & Lara Dimick-Santos

MRI; what can it deliver
Claude Sirlin, MD
UC San Diego, San Diego, CA, USA



Vuppalanchi, Raj 2016 120x160

Transient elastography & other techniques
Raj Vuppalanchi, MBBS
Indiana University School of Medicine, Indianapolis, IN, USA


 #01 - Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial
Michael Middleton, USA
 #02 - A meta-analysis on repeatability of magnetic resonance elastography of liver
Suraj Serai, USA

Saturday 6 May 2017 - Day 2

  Session 5: Quantative assessment of hepatic health
 Chairs: Roberto Calle & Puneet Puri

Siddiqui, Mohammed web 120

Breath tests
Shadab Siddiqui, MD, FACP
Virginia Commonwealth University, Richmond, VA, USA



Everson, Greg 2013

Principles of kinetic measures
Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, USA


 #03 - A real-world, observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study
Miriam Vos, USA
 #04 - Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Alina Allen, USA
 #06 - Serum GP73 as a surrogate biomarker of significant liver fibrosis and cirrhosis in NAFLD
Fengmin Lu, China
 #07 - Plasma collagen type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study
Diana Leeming, Denmark
  Session 6: Challenges Opportunities in integrating 'OMICS
  Chairs: Pierre Bedossa & Shadab Siddiqui

Schuck, Robert 2017 120

Big Data vs. the individual liver from a regulatory perspective
Robert Schuck, PharmD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA



Mato, Jose 2017 120

Big Data vs. the individual liver from a developer's perspective
José María Mato de la Paz, PhD
CIC BioGUNE, Derio, Spain

>Presentation (not available)


Travison, Tom 120

Future scenarios of algorithm building
Tom Travison, PhD
Harvard Medical School & Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA


 #08 - Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis
Sven Francque, Belgium
 #09 - A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH
Dean Hum, France
>Presentation (not available)
 #10 - A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy
Pablo Ortiz, Spain
  Session 7: The Liver in Context
Chairs: Veronica Miller & Arun Sanyal

Sanyal, Arun 2015_def

Integrated Assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD
Arun Sanyal, MD, MBBS
Virginia Commonwealth University, Richmond, VA, USA



Sninsky, John 2017 120

Navigating NASH biomarkers: From discovery to clinical practice
John Sninsky, PhD
CareDx, Brisbane, CA, USA